Abstract

Helicobacter pylori (H. pylori) is a gram-negative bacterium that infects approximately 4.4 billion individuals worldwide. Although the majority of infected individuals remain asymptomatic, this bacterium colonizes the gastric mucosa causing the development of various clinical conditions as peptic ulcers, chronic gastritis and gastric adenocarcinomas and mucosa-associated lymphoid tissue lymphomas, but complications are not limited to gastric ones. Extradigestive pathologies, including metabolic disturbances such as diabetes, obesity and nonalcoholic fatty liver disease, have also been associated with H. pylori infection. However, the underlying mechanisms connecting H. pylori with extragastric metabolic diseases needs to be clarified. Notably, the latest studies on the topic have confirmed that H. pylori infection modulates gut microbiota in humans. Damage in the gut bacterial community (dysbiosis) has been widely related to metabolic dysregulation by affecting adiposity, host energy balance, carbohydrate metabolism, and hormonal modulation, among others. Taking into account that Type 2 diabetic patients are more prone to be H. pylori positive, gut microbiota emerges as putative key factor responsible for this interaction. In this regard, the therapy of choice for H. pylori eradication, based on proton pump inhibitor combined with two or more antibiotics, also alters gut microbiota composition, but consequences on metabolic health of the patients has been scarcely explored. Recent studies from our group showed that, despite decreasing gut bacterial diversity, conventional H. pylori eradication therapy is related to positive changes in glucose and lipid profiles. The mechanistic insights explaining these effects should also be addressed in future research. This review will deal with the role of gut microbiota as the linking factor between H. pylori infection and metabolic diseases, and discussed the impact that gut bacterial modulation by H. pylori eradication treatment can also have in host’s metabolism. For this purpose, new evidence from the latest human studies published in more recent years will be analyzed.

Highlights

  • Helicobacter pylori (H. pylori) is a microaerophilic spiral-shaped Gram-negative bacterium that can colonizes the stomach

  • of studies which have explored the association of the changes in gut microbiota composition

  • Arrows indicate the direction of the relationship between bacterial groups

Read more

Summary

INTRODUCTION

Helicobacter pylori (H. pylori) is a microaerophilic spiral-shaped Gram-negative bacterium that can colonizes the stomach. It has been hypothesized that this local inflammation at the stomach can spread systematically by the release of proinflammatory cytokines This would favor the establishment of a low-grade and chronic inflammation, that is a common feature of H. pylori-associated extra-gastroduodenal disorders including cardiometabolic diseases such as diabetes, atherosclerosis or dyslipidemia [7, 8]. This hypothesis has not been formally confirmed as yet, and knowledge about how inflammation links H. pylori with metabolic disorders is still insufficient. We discuss the latest evidence from human studies on the influence of H. pylori infection and different eradication therapies on the composition of the gut microbiota, with particular focus on the relationship between H. pyloriinduced gut microbiota modifications and host’s metabolic health

PYLORI INFECTION AND METABOLIC DISEASES
Methodology
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call